Market Place
Sourcing Support
Protagonist Exercises U.S. Opt-Out Right for Rusfertide
28 Apr 2026 //
PHARMIWEB
J&J Charts Speedy Launch Of New Psoriasis Pill Icotyde
14 Apr 2026 //
FIERCE PHARMA
Protagonist Announces ICOTYDE Phase 3 Data for Severe Psoriasis
28 Mar 2026 //
PHARMIWEB
US FDA Approves J&J`s Oral Psoriasis Pill
18 Mar 2026 //
REUTERS
Protagonist Prefers $400M From Takeda Over Rusfertide US Profits
26 Feb 2026 //
FIERCE BIOTECH
Takeda, Protagonist Submit Rusfertide (NDA) For Polycythemia Vera
05 Jan 2026 //
BUSINESSWIRE
Protagonist, Takeda Present Rusfertide PV Data at ASH 2025
06 Dec 2025 //
BUSINESSWIRE
Protagonist Therapeutics Presents Rusfertide at ASH Meeting
03 Nov 2025 //
PHARMIWEB
Icotrokinra Shows 28-Week Efficacy, Safety in Ulcerative Colitis
27 Oct 2025 //
PR NEWSWIRE
Protagonist`s Icotrokinra Data in Ulcerative Colitis & Psoriasis
27 Oct 2025 //
PHARMIWEB
Protagonist Reports Icotrokinra UC Data Showing Strong Efficacy
07 Oct 2025 //
PHARMIWEB
Protagonist Presents Icotrokinra Data for Plaque Psoriasis
17 Sep 2025 //
PHARMAWEB
Protagonist`s Icotrokinra Ph 2b Data to be Presented at UEG Week
15 Sep 2025 //
ACCESSWIRE
Protagonist Submits Icotrokinra EMA Application for Psoriasis
11 Sep 2025 //
ACCESSWIRE
Protagonist Therapeutics to Join September 2025 Investment Bank
26 Aug 2025 //
PHARMAWEB
Protagonist Reports Q2 2025 Results, Gives Corporate Update
06 Aug 2025 //
PHARMAWEB
Protagonist Nominates PN-477 Triple Agonist for Obesity
30 Jun 2025 //
ACCESSWIRE
Icotrokinra shows skin clearance in scalp and genital psoriasis
09 May 2025 //
PR NEWSWIRE
Protagonist Announces Presentation on Verify Phase 3 Study
23 Apr 2025 //
ACCESSWIRE
Protagonist Therapeutics Reports Granting of Inducement Award
16 Apr 2025 //
ACCESSWIRE
Icotrokinra meets primary endpoint in ulcerative colitis study
10 Mar 2025 //
PR NEWSWIRE
Protagonist Hosts Investor Event On PV, Rusfertide In New York
29 Jan 2025 //
ACCESSWIRE
Protagonist Reports Durable Hematocrit Control in REVIVE Study
09 Dec 2024 //
ACCESSWIRE
Protagonist to Announce IL-17 Antagonist Development Candidate
19 Nov 2024 //
ACCESSWIRE
Protagonist Announces Positive Results from Iconic Psoriasis Study
18 Nov 2024 //
ACCESSWIRE
Protagonist to Present Final REVIVE Phase 2 Data at ASH 2024
05 Nov 2024 //
ACCESSWIRE
Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024
14 May 2024 //
ACCESSWIRE
Protagonist At Citizens, CapOne Biotech Conferences
07 May 2024 //
ACCESSWIRE
Protagonist Announces Closing of Worldwide Rusfertide License
18 Mar 2024 //
ACCESSWIRE
New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide
21 Feb 2024 //
ACCESSWIRE
Protagonist Earns $10 Million Payment for Phase 2bof JNJ-2113
13 Dec 2023 //
ACCESSWIRE
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at ASH
12 Dec 2023 //
ACCESSWIRE
Protagonist Announces Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113
27 Nov 2023 //
ACCESSWIRE
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications
09 Oct 2023 //
ACCESSWIRE
Durability of Response of Rusfertide in Polycythemia Vera Featured at EHA
09 Jun 2023 //
ACCESSWIRE
Protagonist Reports Positive Results from Ph1 &Preclinical Studies Oral JNJ-2113
12 May 2023 //
PR NEWSWIRE
Protagonist Announces Results from REVIVE Study of Rusfertide
15 Mar 2023 //
ACCESSWIRE
Protagonist Announces Positive Results for Ph2b FRONTIER 1 Trial of Oral IL-23
07 Mar 2023 //
PR NEWSWIRE
